P-gp, which transports lipophilic amphipathic compounds, MRP functions as an efflux pump for amphipathic anionic conjugates, including glutathione-S conjugates and glucuronidated and sulphated compounds (Leier et al, 1994; Muller et al, 1994; Jedlitschky et al, 1996; Loe et al, 1996) . Increasing evidence suggests that an organic anion transporter closely related to MRP, the canalicular multispecific organic acid transporter (cMOAT) (Buchler et al, 1996; Paulusma et al, 1996; Taniguchi et al, 1996) , also plays a role in cytotoxic drug resistance. Although the resistance phenotype of cMOAT has not yet been established in transfection studies, cMOAT has been reported to be overexpressed in cell lines selected for resistance to cisplatin (Taniguchi et al, 1996; Kool et al, 1997) , and transfection of a cMOAT antisense vector was reported to sensitize a liver cancer cell line to cytotoxic drugs (Koike et al, 1997) . In addition, cMOAT-transfected cells have been reported to exhibit enhanced efflux of the natural product drug vincristine (Evers et al, 1998) , and a cMOAT-deficient rat strain has been reported to have decreased excretion of methotrexate into the bile (Masuda et al, 1997) . Together these studies concerning MRP and cMOAT indicate that organic anion transporters are important in cellular resistance to cytotoxic drugs and possibly the excretion of some of these agents into the bile.
The participation of organic anion transporters in cellular resistance and in the hepatobiliary excretion of cytotoxic drugs suggested that other MRP/cMOAT-related pumps might be relevant to the drug treatment of cancer and analyses in our laboratory (MG Belinsky and GD Kruh, unpublished data) and others (Allikmets et al, 1996; Kool et al, 1997) of expressed sequence tag databases suggested that related human transporters exist. Using a variety of experimental approaches, we previously isolated the full-length coding sequences of three MRP/cMOAT-related transporters, designated MOAT-B, MOAT-C and MOAT-D Lee et al, 1998) . These three transporters correspond to previously reported EST sequences designated MRP4, MRP5 and MRP3 (Allikmets et al, 1996; Kool et al, 1997) , respectfully, and in the case of MOAT-C, the partial peptide SMRP (Suzuki et al, 1997) . The possibility that an additional MRP/cMOAT subfamily member might exist was suggested by a recent report describing ARA, a cDNA isolated from an anthracycline-resistant cell line and encoding a predicted 453 residue peptide (Longhurst et al, 1996) . However, our analysis of the reported ARA cDNA indicated that it represents a fused transcript that encodes a small partial peptide of an MRP/cMOAT-related transporter appended carboxyl-terminal to MRP sequences (MG Belinsky and GD Kruh, unpublished observations). Since ARA, located at 16p13.1 (Kuss et al, 1998) , is in close proximity to MRP (16p13.13), and both of these genes have been reported to be amplified in the drug resistant cell line from which ARA was isolated (Longhurst et al, 1996) , it is possible that the ARA cDNA is the product of a rearrangement associated with the MRP amplicon. The detection of cytogenetic abnormalities at 16p in the cell line from which ARA was isolated is consistent with this possibility (O 'Neill et al, 1998) . Together these observations suggest that ARA encodes a partial peptide of a larger transporter whose full-length cDNA has not yet been described. In the present study we isolate the fulllength cDNA of this novel transporter, which we designated MOAT-E. We demonstrate that MOAT-E encodes a 1503 residue ABC transporter that is highly related to MRP, MOAT-D and cMOAT and whose expression is restricted to kidney and liver.
MATERIALS AND METHODS

Isolation of MOAT-E cDNA
Total RNA prepared from human kidney tissue (a gift of Dr D Dexter, Hershey Medical Center) was used to prepare cDNA using the Superscript preamplification system (GibcoBRL, Gaithersberg, MD, USA) according to the manufacturer's instructions. Aliquots of this cDNA were used as template to generate three overlapping PCR fragments, using oligonucleotide primers 5′GGGGCGGCCGCACCATGGCCGCGCCTGCT-GAGC3′ (forward) and 5′GTCTACGACACCAGGGTCAAC3′ (reverse); 5′CTGCCTGGAAGAAGTTGACC3′ (forward) and 5′CTGGAATGTCCACGTCAACC3′ (reverse); 5′GGAGACA-GACACGGTTGACG3′ (forward) and 5′GCCTCGAGT-CAGACCAGGCCTGACTCC3′ (reverse). The first three oligonucleotide primers were designed based upon the predicted exons of a human genomic clone (GenBank accession number U91318), and the last three oligonucleotide primers were based upon the reported sequence of ARA (Longhurst et al, 1996) . PCR products were inserted into pBluescript SK-(Stratagene, La Jolla, CA, USA) using the restriction sites located at the 5′ ends of the first and last oligonucleotide primers, and natural restriction sites located within the MOAT-E cDNA. Nucleotide sequence analysis was performed using an ABI 377 DNA sequencer, and the resulting sequences were assembled using the Sequencher program (Gene Codes Corporation, Ann Arbor, MI, USA). Protein sequence analysis was performed using the Wisconsin Package Version 9.1 (Genetics Computer Group, Madison, WI, USA).
RNA blot analysis
Blots containing poly A + RNA isolated from human tissues were purchased from Clontech (Palo Alto, CA, USA) and hybridized according to the manufacturer's directions. The 5′ MOAT-E probe encompassed nucleotides 342-656 (amino acids 114-219) and the 3′ MOAT-E probe encompassed nucleotides 3559-4341 (amino acids 1187-1447) of the cDNA.
RESULTS
Isolation of MOAT-E cDNA
We analysed the sequence of ARA (Longhurst et al, 1996) , a cDNA isolated from a drug-resistant cell line, and found that it is a fused transcript in which 161 nucleotides of MRP sequence are fused to 1775 nucleotides of downstream sequences encoding an MRP/cMOAT-related transporter. The predicted peptide encoded by the downstream sequences was 438 amino acids (residues 16-453), less than one-third the size of other MRP/cMOAT subfamily transporters. A schematic of the predicted fusion protein encoded by the ARA cDNA is shown in Figure 1 . These observations suggested that the predicted ARA coding sequence did not represent a protein expressed in normal cells, and that the complete coding sequence of a novel MRP/cMOAT-related transporter remained to be isolated. Consistent with this possibility, database analysis revealed a genomic clone (GenBank accession number U91318), the predicted exons of which encoded a large potential protein whose carboxyl-terminus was nearly identical to the 438 residue predicted peptide of ARA. To isolate the full-length coding sequence of the peptide encoded by the ARA downstream sequences, we used a reverse transcriptase polymerase chain reaction (RT-PCR) approach in which cDNA prepared from human kidney RNA served as template for oligonucleotide primers that were designed based upon genomic clone U91318 and the reported ARA sequence. This approach yielded a total of ~ 4.5 kb of overlapping cDNA clones. Nucleotide sequence analysis revealed an open reading frame of 1503 residues, the predicted protein of which we designated MOAT-E. 
Analysis of the MOAT-E predicted protein
The predicted amino acid sequence of MOAT-E is shown in Figure  2 . Typical features of ABC transporters are present in MOAT-E. Overall, the protein is composed of hydrophobic membrane spanning domains and two nucleotide binding folds (NBFs). Conserved Walker A and B ATP binding motifs, and a conserved C motif, the signature sequence of ABC transporters, are present in the NBFs. As shown schematically in Figure 1 , the carboxyl-terminus of the MOAT-E predicted protein (residues 999-1503) corresponds to the MRP-related peptide encoded by ARA (residues 16-453). However, the respective amino acid sequences are not completely identical (96%). Compared to MOAT-E, ARA harbours a small deletion and four amino acid substitutions. MOAT-E residues 1080-1168 are absent in ARA, and MOAT-E residues A-1215, L-1287, L-1335 and S-1386, are represented in ARA by threonine, phenylalanine, valine and cysteine residues respectively. NBFs are conserved features of ABC transporters, and the degree of similarity between the NBFs of family members indicates the potential for functional conservation (Higgins, 1992) . Comparison of the NBFs of MOAT-E with other human ABC transporters indicated that they were most closely related to MRP, cMOAT and three MRP/cMOAT-related transporters we recently described, MOAT-B, MOAT-C and MOAT-D (Table 1) Lee et al, 1998) . Among these transporters, the NBFs of MOAT-E (NBF1/NBF2) shared the highest degree of identity with those of MRP (61/62%), MOAT-D (59/59%) and cMOAT (55/59%). A comparison of the amino acid sequences of the MOAT-E NBFs with those of related transporters is shown in Figure 3A . A distinguishing feature highlighted by these alignments is the presence of small insertions in the NBF1 of SUR and MDR1 that are absent in the NBF1 of MOAT-E, other MRP/ cMOAT subfamily members, and CFTR. Consistent with the analysis of NBFs, overall the MOAT-E predicted protein shared the highest degree of amino acid identity with MRP (45%), MOAT-D (44%) and cMOAT (39%) ( Table 1) . MOAT-E was less well related to MOAT-B and MOAT-C, with which it shared 34% and 31% identity respectively.
A comparison of the hydropathy profiles of MOAT-D with other MRP/cMOAT subfamily transporters, and P-gp, is shown in Figure 3B . Similar to MRP, MOAT-D and cMOAT, MOAT-E has three membrane spanning domains, including an amino-terminal membrane spanning domain that is not present in MOAT-B, MOAT-C or most other ABC transporters, such as P-gp. A 5 + 6 + 6 configuration of transmembrane spanning helices has been proposed for MRP and cMOAT, in which the amino-terminal membrane spanning domain harbours five transmembrane spanning helices, and six transmembrane helices are located in both the second and third membrane spanning domains (Bakos et al, 1996 ; H e a r t B r a i n P l a c e n t a L u n g L i v e r S k e l e t a l m u s c l e K i d n e y P a n c r e a s S p l e e n T h y m u s The structure of MOAT-D is consistent with this . A combination of computer-assisted analysis using the TMAP program (Persson and Argos, 1994) and inspection of an alignment of MOAT-E with MRP, indicated that a 5 + 6 + 6 configuration of transmembrane helices is possible for MOAT-E. This configuration of transmembrane spanning helices is shown in Figure 2 . Using computer-assisted analysis alone another configuration of transmembrane spanning helices was predicted (5 + 6 + 4). MRP has been reported to have two N-linked glycosylation sites in its amino-terminus, and another site located between the first and second transmembrane spanning helix of its third membrane spanning domain (Hipfner et al, 1997) . A potential amino-terminal N-glycosylation site was conserved in MOAT-E (Asn-15).
P r o s t a t e T e s t i s O v a r y S m a l l i n t e s t i n e
Expression pattern of MOAT-E
ARA was reported to be expressed as a 2.2 kb transcript in the anthracycline resistant cell line from which it was isolated (Longhurst et al, 1996) . However, an RNA blot of normal human tissues using ARA sequences as a probe has not been reported. If MOAT-E represents the normal transcript of ARA, we hypothesized that it should be expressed as a larger sized transcript. To test this hypothesis, and gain insight into the possible function of MOAT-E, its expression pattern in a variety of human tissues was examined. Figure 4 (upper panel) shows an RNA blot using a MOAT-E probe derived from 5′ sequences of the cDNA that are not present in ARA. As expected, a MOAT-E transcript (~ 6 kb) that is considerably larger than the reported ARA transcript was detected. In addition, MOAT-E expression was strikingly restricted. Of the 16 tissues analysed, MOAT-E transcript was detected only in liver and kidney. This expression pattern suggests that MOAT-E subserves a specialized function in these two excretory tissues. To confirm that an identical 6 kb transcript was detected using a probe derived from sequences present in ARA, another set of membranes containing RNAs prepared from human tissues was hybridized with a 3′ MOAT-E probe. As shown in Figure 4 (lower panel) this probe also detected 6 kb transcripts in liver and kidney (some degradation is evident in the liver sample).
MOAT-E helps to define the MRP/cMOAT evolutionary cluster
A cluster analysis of eukaryotic ABC transporters generated using the PILEUP program of the GCG group package is shown in Figure 5 . This analysis indicates that the known eukaryotic ABC transporters fall into five families. The MRP/cMOAT subfamily transporters (MRP, cMOAT, MOAT-B, MOAT-C, MOAT-D and MOAT-E) reside within a single cluster, which currently contains the largest number of human ABC transporters. The close relationship between MRP, cMOAT, MOAT-D and MOAT-E is reflected in the close grouping of these four transporters within the cluster. Also within the MRP/cMOAT cluster are the yeast transporters YCF1 and YOR1, and the leishmania transporter PGPA. Like MRP and cMOAT, these three proteins have been reported to transport organic anions (Ouellette et al, 1990; Gui et al, 1996; Li et al, 1996) . However, two proteins that are not known to function as organic anion transporters also reside within this cluster. The cystic fibrosis transmembrane conductance regulator, CFTR, functions as an ATP-regulated chloride channel, and the sulphonyl urea receptor, SUR, functions to regulate potassium channels.
DISCUSSION
We previously reported the complete coding sequences of MOAT-B (MRP4), MOAT-C (MRP5) and MOAT-D (MRP3), three MRP/ cMOAT subfamily members Lee et al, 1998) . Based upon the degree of amino acid identity and overall protein topology, we found that the MRP/cMOAT subfamily could be divided into two groups. The first group was composed of MRP, cMOAT and MOAT-D, three transporters that share a high degree of amino acid identity (47-57%), and a common topology characterized by a third membrane spanning domain located at their aminotermini. In contrast, MOAT-B and MOAT-C were somewhat less well-related to MRP (39% and 36% respectively) and did not have amino-terminal hydrophobic extensions. The isolation of MOAT-E now extends the number of full-length MRP/cMOAT-related transporters to four, and helps to further define this subfamily. Of the known MRP/cMOAT subfamily members, MOAT-E is most closely related to MRP (45%), MOAT-D (44%) and cMOAT (39%). In addition, similar to topological models proposed for the latter three protein, analysis of the primary structure of MOAT-E suggests a model in which 17 transmembrane spanning helices are distributed within three membrane spanning domains in a 5 + 6 + 6 configuration. Thus, MOAT-E belongs to the first group of MRP/cMOATtransporters we described. Two recently reported transporters isolated from rat liver, MLP-1 and MLP-2 (Hirohashi et al, 1998) , are orthologues of MOAT-E (81.5% identity) and MOAT-D (79.6% identity), respectively. Based upon the close relationship of MOAT-E to MRP and cMOAT, we speculate that it may also function as an organic anion transporter. MRP has been reported to transport a variety of amphiphilic conjugates, including several glutathione S-conjugates, such as the endogenous substrates LTC 4 and oxidized glutathione, and xenobiotic conjugates such as DNP-glutathione and monoglutathionyl melphalan (Leier et al, 1994 Muller et al, 1994) . In addition, several sulphated and glucuronidated compounds are MRP substrates Loe et al, 1996) . In the case of cMOAT, genetic and biochemical studies of rat strains that are deficient in this protein originally indicated that it functions as an important transporter of amphipathic conjugates into bile (Jansen et al, 1985; Mikami et al, 1986 ). More recently, several studies using the cloned cMOAT cDNA have confirmed this substrate specificity. Transient expression of rat cMOAT in COS cells and Xenopus laevis oocytes has been reported to induce increased cellular efflux of 2,4-dinitrophenyl-S-glutathione and LTC 4 (Madon et al, 1997) . In addition, enhanced ATP-dependent uptake of glutathione S-conjugates by cMOAT-enriched membrane vesicles prepared from insect cells (Remon et al, 1998) and stably transfected cells (Madon et al, 1997; Evers et al, 1998; Ito et al, 1998) has been reported. Studies using the MOAT-E cDNA should determine whether it shares the substrate specificity of MRP and cMOAT, or possibly transports a distinct class of compounds.
Using RNA blot analysis, we found that MOAT-E transcript was abundant in liver and kidney, but undetectable in many other human tissues. This expression pattern is distinct from those of other MRP/cMOAT subfamily transporters. MRP and MOAT-C are widely expressed, cMOAT is expressed at high levels in the liver, and low levels in small intestine and kidney, MOAT-B is highly expressed in prostate, but also expressed in other tissues, and MOAT-D is expressed in colon, pancreas, liver and kidney, with lower levels in small intestine, prostate and placenta Buchler et al, 1996; Paulusma et al, 1996; Kool et al, 1997; Suzuki et al, 1997; Schaub et al, 1997; Belinsky et al, 1998; Lee et al, 1998) . The MOAT-E expression pattern suggests that it may participate in hepatobiliary and renal excretion of organic anions. While cMOAT is a major pump for organic anions in liver, the hepatobiliary excretion of organic anions is not completely abolished in cMOAT-deficient rat strains, suggesting the existence of other organic anion transporters. MRP is expressed in hepatocytes, but its level is low, and it is localized at the lateral membrane which does not communicate with bile canaliculi (Mayer et al, 1995) . MOAT-E may therefore function as an alternative system to cMOAT for the hepatobiliary excretion of organic anions. It is also possible, however, that MOAT-E subserves a different function in the liver. The abundant expression of MOAT-E transcript in kidney is particularly interesting. While cMOAT is expressed in the kidney, its expression level is low, and the urinary excretion of organic anions has been reported to be largely unaffected in cMOAT-deficient TRrats (Huber et al, 1987; de Vries et al, 1989) . Thus MOAT-E may function as an ATP-dependent transporter of organic anions into urine. The excretion of organic anions into urine is particularly relevant to methotrexate. A role for cMOAT in the hepatobiliary excretion of this agent has been proposed based upon the observation that cMOAT-deficient mice have increased plasma levels, and decreased biliary excretion of this agent (Masuda et al, 1997) . However, in humans methotrexate is predominately excreted into the urine (Allegra and Grem, 1997). MOAT-E is therefore a potential candidate for the renal transporter involved in the urinary excretion of this agent. MOAT-D is also well-expressed in kidney and may therefore also play a role in organic anion excretion by the kidney. Additional studies should determine whether MOAT-E is involved in the renal and hepatobiliary excretion of organic anions, and whether it plays a role in the cellular detoxification of natural product cytotoxic drugs.
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